High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.

摘要: Relapsed mantle cell lymphoma is a radiation-sensitive malignancy that unlikely to be cured by treatment with conventional high-dose therapy and autologous stem transplantation. We tested the safety efficacy of using CD20-specific monoclonal antibody conjugated (131)I deliver radiation selectively all sites. Patients relapsed or refractory received infusions (131)I-labeled (Tositumomab). The dose was 1.7 mg/kg body weight, amount calibrated 20 25 Gy vital normal organs. This followed 10 days later administration etoposide (30-60 mg/kg), cyclophosphamide (60-100 infusion cryopreserved cells. 16 patients in this study had median 3 prior treatments, 7 chemotherapy-resistant disease. 510 mCi (18.87 GBq). There were no therapy-related deaths. Among 11 conventionally measurable disease at time treatment, respective complete overall response rates 91% 100%. Fifteen remain alive, 12 have progression 6 57 months from transplantation 97 diagnosis. Overall survival years estimated 93%, progression-free 61%. High-dose (131)I-Tositumomab, etoposide, results high remission rate may provide long-term disease-free for lymphoma.